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Cold-dependent activation of complement (CDAC) is a 
phenomenon characterized by low hemolytic comple- 
ment activity in chilled serum. Complement component 
levels are normal when measured immunologically, and 
there is normal hemolytic activity in EDTA plasma or 
serum maintained at 37°C. Little attention has been paid 
to CDAC except in Japan, and current unfamiliarity with 
it, even by clinical immunologists, can lead to confusion 
and unnecessary laboratory tests. A 66-year-old patient 
with a complex medical history is described whose com- 
plement tests showed abnormalities characteristic of 
CDAC. Evidence for classical complement pathway ac- 
tivation in the cold was obtained by CHso measurements, 
by hemolytic C4 determinations, by C4a, C3a, and C4d 
generation, and by quantitating Clg-CI~-(C1 inhibitor)2 
complexes. A good correlation was observed among 
these parameters. Cryoprecipitates were absent. CDAC 
activity has persisted for over 5 years and is greater at 13 
than at 4°C. Activation is ablated by heating at 56°C and 
restored by the addition of C1 to the heated serum. 
Adsorption by streptococcal protein G-Sepharose and 
precipitation by 2.5% polyethylene glycol support the 
hypothesis that CDAC is caused by aggregated IgG. The 
CDAC factor(s) also induces complement activation in 
normal serum but has not interfered with Raji cell or Clq 
binding tests or with FACS analysis. More limited studies 
of a second individual experiencing CDAC yielded similar 
results. 
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INTRODUCTION 
Discrepancies between hemolytic complement ac- 
tivity in serum versus plasma have been reported in 
abstracts published beginning in 1970 (1-4). Al- 
though the initial emphasis was on the possible role 
of blood coagulation factors (I-3, 5), it was subse- 
quently discovered that the serum abnormality was 
associated with cooling the serum in vitro (4, 6-14). 
The usual features of cold-dependent activation of 
complement (CDAC) include low CHs0, low hemo- 
lytic C4, and normal hemolytic C5-C9 in chilled 
serum, whereas these values are nearly normal in 
EDTA plasma and in serum kept at 37°C. In addi- 
tion, immunologic measurements of complement 
components are normal even in chilled serum. C1 
inhibitor (C1 INH) levels also are normal, and 
precipitating cryoglobulins and cryofibrinogens are 
absent. Although there have been unreported cases, 
apparently only 11 patients with CDAC have been 
reported in the United States (1-4, 10). In contrast, 
more than 40 such individuals have been described 
by Japanese investigators (5-9, 11-13). Many of 
these patients had chronic liver disease, and 5 of 
574 patients with primary renal disease had CDAC 
(9). In addition, Akasaki et al. (9) found evidence of 
CDAC in 5 of 8100 apparently healthy Japanese. 
CASE REPORTS 
Patient  i 
Patient 1 was a 66-year-old woman who was 
initially seen by us in 1985 because of swelling and 
burning of the tongue. The complex medical history 
included hyperparathyroidism with resection of a 
parathyroid adenoma, thyroid nodule resection, 
splenectomy for splenic artery aneurysm, border- 
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Table I. Initial Complement Measurements on Sera of Patients 1 and 2 ~ 
Patient 1 Normal Patient 2 Normal b 
<22 u 104-188 0 64 
24.3 mg/dl 14-20 
153 mg/dl 80-231 86 mg/dl 80-231 
25 mg/dl 10-46 20 mg/dl 10-46 
15.5 mg/dl 11-23 






Functional C1 INH 










32,000 256,000 32,000 64,000 
12,500 12,800 1,200 6,400 
64,000 96,000 4,800 6,400 
0 64,000 24 24,000 
96,000 192,000 96,000 64,000 
128,000 128,000 64,000 64,000 
128,000 128,000 64,000 64,000 
64,000 128,000 48,000 48,000 
16,000 16,000 24,000 16,000 
'~fests performed elsewhere before being evaluated by us. 
bNormal functional serum titers can vary on different days. 
line polycythemia, a previous (but unsubstantiated) 
diagnosis of von Willebrand's disease, glaucoma, 
and hypertension. Aside from multiple surgical 
scars, the physical examination was unremarkable; 
the tongue appeared normal at that time. 
Considering hereditary angioedema as a possible 
cause of the tongue swelling, a gastroenterologist 
had obtained C3 and C4 levels and a CHs0. The 
former were normal, but the CHso was immeasur- 
ably low. These tests were repeated together with 
other measurements noted in Table I. The most 
striking result was the absence of measurable he- 
molytic C4 activity in the presence of a normal C4 
level as measured immunologically. Subsequent 
tests showed similar results except that hemolytic 
C2 was only one-fourth of control levels. 
The following additional abnormalities have been 
noted: WBC of 13,500, with 63% lymphocytes and 
increased platelets; Hgb, Hct, RBC, red cell mass, 
and total blood volume indicative of mild polycy- 
themia; serum protein electrophoresis showing a 
polyclonal increase in ~/-globulins; IgG elevated to 
1750 mg/dl and IgA elevated to 524 mg/dl, with a 
normal IgM and IgE; IgG subclass measurements 
showing only IgG1 to be increased; C3b increased 
on immunofixation but normal alternative pathway 
activation following inulin stimulation; Clq binding 
of I4% (borderline, I3-I6%); a Raji cell test of 254 
~g AHG Eq/ml (normal, <50); and a rheumatoid 
factor titer of 1:20 in chilled serum and negative at 
1:20 in 37°C serum. 
The most relevant normal or negative tests were 
the urinalysis, erythrocyte sedimentation rate (3 
mm/hr), C-reactive protein, antinuclear antibody, 
anti-DNA, hepatitis B antigens and antibodies, vi- 
rus antibody screen, and cold agglutinins. In three 
tests there was an absence of cryoglobulin, cryofi- 
brinogen, or heparin-precipitable cryoprotein after 
7 days' observation and no decrease in C4 binding 
protein. Alpha-1 protease inhibitor and antithrom- 
bin III levels were normal. Tests for anti- 
mitochondrial, anti-smooth muscle, anti-parietal 
cell, anti-thyroglobulin, and anti-microsomal anti- 
bodies have been negative, as well as tests for von 
Willebrand's disease and coagulation abnormali- 
ties. Most liver function tests were normal. Subse- 
quently a diagnosis of probable lymphocytic leuke- 
mia has been made based on pers is t ing 
lymphocytosis and 5% of cells in the bone marrow 
appearing to be lymphoblasts. Flow cytometry in 
1986 showed a T cell lymphocytosis with atypical 
surface phenotype. The patient has not experienced 
significant adverse symptoms on exposure to cold. 
Patient 2 
Patient 2, a 27-year-old married female, had for- 
tuitously been found in 1984 to have an immeasur- 
ably low CHs0 level on three occasions when she 
served as a control for complement tests. Her 
antinuclear antibody test had been positive at a 
dilution of 1:320 (homogeneous pattern), she had 
been experiencing Raynaud's phenomenon for 
about 10 years, and during the preceding year she 
had a marked facial reaction to sun exposure. The 
medical history included recurrent urinary tract 
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infections with pyelonephritis, recurrent staphylo- 
coccal infections including septic arthritis of the left 
knee, perirectal abscess, and deep venous throm- 
boses. Physical examination was essentially within 
normal limits except for evidence of mitral valve 
prolapse. She was brought to our attention when we 
presented patient 1 at a local conference. 
Complement measurements (Table I) showed 
strikingly decreased CHs0 and hemolytic C4 values 
in the presence of normal C4 levels as measured 
immunologically. Subsequent immunologic mea- 
surements of Clq and C1 inhibitor were normal, 
and cryoglobulins could not be demonstrated in two 
tests lasting 7 days. Supporting a clinical diagnosis 
of probable systemic lupus erythematosus, the ho- 
mogeneous ANA test titer had risen to 1:1280 by 
1987, and DNA binding by the Fan" test was ele- 
vated at 28%. Tests for anti-ENA antibodies have 
been positive, but anti-RNP, anti-Sm, anti-Ro, and 
anti-La tests have been negative. Other negative or 
normal results have included anti-cardiolipin anti- 
bodies, VDRL, WBC and differential, hepatitis B 
surface antigen, and nasal and rectal swabs for 
Staphylococcus aureus. The patient's parents and 
two siblings had been found to have normal CHs0 
levels and normal C4, C3, and C1 inhibitor values 
when measured immunologically. 
More recently patient 2 has experienced recur- 
rent arthralgias and episodes of pleuritic chest pain, 
and there have been two spontaneous abortions. 
Synovectomy of the left knee has been followed by 
the placement of a total knee prosthesis. Following 
sun exposure in 1990 she had a severe exacerbation 
of her disease including neurological symptoms. 
Exposure to cold has not produced difficulty other 
than Raynaud's phenomenon. 
MATERIALS AND METHODS 
Some blood samples were clotted for 1 hr at 4°C, 
centrifuged at that temperature, snap-frozen in ali- 
quots in liquid N 2, and stored at -70°C; other blood 
samples were placed in tubes prewarmed to 37°C, 
transported to the laboratory in warmed sand at 
37°C, centrifuged at 37°C, and immediately snap- 
frozen in aliquots; and additional blood samples 
were collected in tubes containing EDTA or heparin 
and the plasma snap-frozen in aliquots after centrif- 
ugation at 4°C. CHs0, hemolytic C4, and hemolytic 
C 1 were assayed according to the methods of Kabat 
and Mayer (15), Cooper and Muller-Eberhard (16), 
and Borsos and Rapp (17), respectively. Similar 
procedures were used in another laboratory in the 
tests reported in Table I. Our hemolytic C4 values 
are based on reciprocal serum dilutions where Z = 
1 (16). C4a and C3a were determined by radioim- 
munoassay using an Upjohn Co. kit, and C4d/C4 
ratios were measured by rocket immunoelectro- 
phoresis as described by Milgrom et al. (18). Ex- 
periments involving mixtures of serum containing 
CDAC factor(s), or precipitates therefrom, and nor- 
mal serum employed the procedure of Atkinson et 
al. (10). 
Clg-CI~-(C1 INH)2 Assays 
Anti-Cls serum was obtained from a goat immu- 
nized with Cls purified by the method of Sim (19), 
the antiserum being purified by affinity chromatog- 
raphy. C1 INH was purified by the method of 
Salvesen et al. (20). Clg-CI~-(C1 INH)2 complexes 
were measured by the enzyme-linked immunosor- 
bent assay (ELISA) procedure described by Harpel 
and Cooper (21) and subsequently modified accord- 
ing to the method of Nilsson and Back (22). Briefly, 
ELISA plates were coated overnight at 4°C with 1 
ixg/ml of the afffinity-purified goat anti-C 1 s or F(ab') 2 
fragments therefrom. Following blocking with gel- 
atin solution, test serum diluted in phosphate- 
buffered saline (PBS)-Tween with 20 mM EDTA 
was introduced into the wells, and after overnight 
incubation at 4°C Clg--CI~'-(C1 INH) 2 complexes 
were quantitated following sequential reactions 
with 2 ~g/ml mouse monoclonal anti-C1 INH, 
1:5500 human adsorbed peroxidase-conjugated goat 
anti-mouse IgG serum (Caltag Labs, San Francisco, 
CA), and enzyme substrate. Control wells were 
coated with normal goat IgG. In agreement with 
Nilsson et al. (22), it was found that in order to 
compare results at different serum dilutions, it is 
necessary to precipitate out inhibitory Clqrs com- 
plexes by the addition of polyethylene glycol (PEG) 
6000 to a final concentration of 6% (w/v) before 
diluting the serum with EDTA-containing buffer. 
Resulting OD readings were compared with a linear 
standard curve generated by serial dilutions of 
PEG-precipitated normal human serum which had 
been activated by 1 mg/ml of heat-aggregated 
v-globulin and which had arbitrarily been assigned a 
value of 1000 units (23). The intraassay coefficient 
of variation averaged -5.9%, and previous freezing 
and thawing of sera three times did not influence the 
results. 
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Protein G Adsorption Tests 
Protein G-Sepharose was purchased from Phar- 
macia (Piscataway, N J). Patient or control EDTA 
plasma was agitated for 30 min at room temperature 
(RT) with a double volume of washed protein 
G - S e p h a r o s e  beads  or anti-human albumin- 
conjugated Sepharose. CaCI2 was added to the 
supernatants to a concentration of 14 mM. After 
removing the clots, the tubes were incubated for 2.5 
hr at 12°C and divided into aliquots for C4d/C4 and 
CIt-Clg--(C1 INH)2 tests. Controls included unad- 
sorbed plasma. 
Inhibition by Heat and Restoration with C1 
A redissolved euglobulin precipitate of normal 
serum was the source of the C1 used in this test as 
well as in the hemolytic assays. Aliquots of patient 
1 serum obtained at 37°C were refrozen at once or 
were incubated for 2 hr at 4°C before refreezing. 
Other aliquots were heated at 56°C for 15 min 
before being either immediately refrozen, incubated 
for 2 hr at 4°C, incubated for 2 hr at 4°C following 
the addition of C1, or incubated for 2 hr at 4°C after 
the addition of C1 which had previously been 
heated at 56°C for 30 min. The C1 was dissolved in 
PBS containing 0.15 mM CaCI2, and either this or 
buffer alone was added to 3 vol of serum in all 
aliquots. The final concentration of reconstituted 
C I approximated that of normal serum. The various 
aliquots were subdivided for subsequent testing for 
C4d/C4 ratio, Clg-CI~-(CI INH) 2 content and he- 
molytic C4. 
R E S U L T S  
Recognition o f  CDAC 
Attention initially was focused on the striking 
discrepancy between patient l 's  total absence of C4 
hemolytic activity and the presence of normal C4 
levels as measured immunologically. Considering 
the possibility of an unusual C4 abnormality (e.g., 
abnormally glycosylated or incompletely processed 
pro-C4), sera from eight family members were 
tested for CHs0, hemolytic C4, and C4 antigen, but 
all were normal. Activation of the classical pathway 
would be the most obvious possibility, but lack of 
clinical evidence for immune complex disease, nor- 
mal ESR, absence of precipitable cryoproteins, 
normal levels of Clq,  C4, and C3 antigen, nearly 
Table II. Anaphylatoxin Measurements by Radioimmunoassay 
C4a C3a 
(ng/ml) (ng/ml) 
A. Specimens collected at 4°C 
Patient 1 serum 
Normal serum 
Patient 1 serum + zymosan 
+ aggregated IgG 17,756 
Normal serum + zymosan 
+ aggregated IgG 11,620 
Patient 1 EDTA plasma 181 
Normal EDTA plasma 175 
B. Patient 1 specimens collected at 37°C 
16,980 (96) a 51,250 (31) 





Hours incubated at 37°C 
0 289 (1.3) 4,600 (7.7) 
1.5 465 (2.1) 5,016 (8.4) 
3 959 (4.3) 3,760 (6.3) 
Hours incubated at 4°C 
0 587 (2.6) 3,280 (5.5) 
1.5 4,413 (19.6) 7,145 (11.9) 
3 23,092 (100) 8,983 (15.0) 
aPercentage of activatable C4 or C3. 
normal levels of hemolytic C2, and exclusion of C1 
inhibitor deficiency at first detracted from this con- 
sideration. However, measurement of C4a and C3a 
serum levels provided striking evidence of C4 and 
C3 cleavage, but unlike most cases of in vivo 
complement activation, the total activatable C4 and 
C3 levels also were somewhat above normal (Table 
IIA). Although there was a substantial amount of 
C3a detected, the percentage C3 cleavage was 
lower than C4 cleavage as is common in fluid-phase 
classical complement pathway activation. Of even 
greater interest was the concomitant normal C4a 
level measured in EDTA plasma, and subsequently 
it was shown that CH50 and hemolytic C2 levels also 
were normal in patient l ' s  EDTA or citrate plasma. 
These data suggested the diagnosis of CDAC. It 
resulted from the procedure at that time of sending 
blood for serum hemolytic complement levels to the 
pathology laboratory on ice, whereas in EDTA 
plasma C 1 activation is inhibited by the chelation of 
Ca 2+ by EDTA. 
Testing for CDAC 
In general, documenting CDAC involves demon- 
strating functional classical pathway activation in 
chilled serum but not in (a) cold EDTA plasma or 
(b) serum obtained from blood maintained at 37°C. 
The latter requires meticulous specimen collection 
(see Materials and Methods) but permits one to 
study mechanisms of CDAC by subsequent con- 
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Incubation 4°C 13°C 24°C none 
C4d/C4 ratio 2.37 3.06 1.19 1.13 
CI~-CIT-(C1 INH)2 337 a 1t57 177 85 
Hemolytic C4 20 b <5 90 100 
a ELISA units 
b % of normal 
Fig. 1. Rocket immunoelectrophoresis for C4d/C4 ratio, CIg- 
C 1 f'--(C 1 INH)z ELISA measurements and hemolytic C4 titers on 
freshly thawed patient 1 37°C serum (12-8-86) before and after 4 
hr at 4, 13, and 24°C. 
trolled activation in the cold. As in some previously 
reported cases, our attention was directed to a 
complement abnormality by finding an unexpect- 
edly low CHso level, and subsequent CHso measure- 
ments in warm and chilled serum and in EDTA 
plasma yielded a pattern typical for CDAC. The 
CHso levels in chilled serum from patient 1 all were 
<22 u (N = 6), 37°C serum levels were 110 - 13 u 
(N = 7), and EDTA plasma levels were 78 and 105 
u. However, other methods of measuring comple- 
ment activation provide more incisive evidence of 
classical pathway activation, greater sensitivity, or 
more convenience. 
Figure 1 shows measurements of CDAC activity 
in freshly thawed serum from patient 1 obtained on 
12.8-86 before and after incubation for 4 hr at 24, 13, 
or 4°C. Measurements were performed by rocket 
immunoelectrophoresis (IEP) for C4d generation, 
hemolytic C4 titration, and CI~-CI~-(C1 INH) 2 
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Fig. 2. Measurements of percentage initial hemolytic activity 
(A), C4d/C4 ratio (O), and CIg-Clf'-(CI INH)2 ELISA units (X) 
before and after incubating patient 1 serum obtained at 37°C 
(4-12-88) for 4 hr at 24, 13, or 4°C. 
achieved by measuring planimetrically the area en- 
compassed by the upper C4d rocket and the area of 
the more sharply delineated C4 rocket; normally the 
C4d/C4 ratio is <1.2 (18). For comparison with the 
other data, the hemolytic C4 titers are expressed as 
a percentage of the unincubated specimen value. 
Figure 2 shows similar evidence for CDAC activity 
as assessed by these three tests in serum obtained 
on 4-12-88; additional tests yielded the same results 
on serum obtained on 4-4-90. The finding of greater 
CDAC activity at 13 than at 4°C was confirmed in 
five additional experiments including three using 
patient 2 serum. Earlier observations employing 
CHs0 measurements of serum from patient 1 
showed no evidence of CDAC at 32 or 29°C, but 
beginning complement activation was observed at 
26°C. Serum obtained from patient I at 37°C re- 
quired chilling for 3 hr at 4°C to achieve maximal 
complement activation. As shown in Table IIB, 
measurements of C4a and C3a generation in chilled 
patient 1 serum or recalcified EDTA plasma yielded 
results similar to those of the previously mentioned 
tests. Normal serum does not show this response to 
cold. Patient 2 serum also showed greater C4a 
generation at 4 than at 37°C, while C4a and C3a 
levels in EDTA plasma were significantly lower 
(data not shown). Another test for CDAC factor(s) 
is to demonstrate its capacity to activate comple- 
ment in normal serum after mixing in the cold (10). 
The higher level of CI~CI?-(C1 INH)2 complexes 
and lower hemolytic C4 values seen in column 3 in 
Table III than in column 5 indicate that activation of 
normal serum complement has occurred. The fact 
Journal of  Clinical Immunology, Vol. 12, No. 5, 1992 
COLD-DEPENDENT ACTIVATION OF COMPLEMENT 367 
Table IH. Activation of Normal Serum Complement by Incubation with CDAC Serum 
at 4°C for 24 hr 
(1) (2) (3) (4) (5) 
K M s " + V B  ÷+b P t . l  c + V B  +÷ Pt. Is + KMs BZs ~ +  KMs (1 + 2 )  
C4d/C4 ratio 1.0 
CI~-C I~'-(C 1 INH)2 
(ELISA units) 33 
Hemolytic C4 
(% normal) 49 
2.33 >2.62 1.0 
470 774 25 503 
0 <2 79 49 
aNormal serum. 
bVeronal buffer with Ca and Mg. 
CCDAC patient serum. 
that the C4d/C4 ratio in column 3 exceeds the 
average of columns 1 and 2 also supports this 
conclusion. Similar results were obtained in six 
other experiments. 
Assessing the Mechanisms of CDAC 
Supporting previous data suggesting that the 
CDAC factor(s) is IgG (10), Table IV shows results 
representative of three experiments in which pa- 
tient 1 plasma and control EDTA plasma were 
batched-adsorbed by protein G-Sepharose. In other 
Table IV. Adsorption of CDAC Factor(s) from EDTA Plasma 





G, 12°C i2°C 
Patient I a 
C4d/C4 ratio 1.05 2.17 1.10 
CI~-Clt-(C1 INH)2 0,436 b 1.440 0.322 
Normal ~ 
C4d/C4 ratio 1.13 1.14 !. 15 
CI~-CI~--(CI iNH)2 0.589 0.454 0.382 
1.41 
0.900 
~EDTA plasma recalcified after adsorption. 
hOD value. 
experiments it was shown that more than 99% of the 
IgG was removed by this procedure. Results of both 
the C4/C4d and the Clg--CI~-(C1 INH) 2 tests indi- 
cate an accompanying marked loss in CDAC activ- 
ity which was much greater than that following 
adsorption with anti-human serum albumin Sepha- 
rose. It was necessary to do these adsorptions in 
EDTA plasma (followed by recalcification) rather 
than in serum, because the latter procedure resulted 
in significant complement activation. 
Table V shows the results of an experiment in 
which patient 1 and normal sera were precipitated 
by 2.5% PEG in PBS with 20 mM EDTA for 2 hr at 
4°C. After washing with 2.5% PEG in PBS, the 
precipitates were (largely) dissolved in 37°C 
Veronal buffer, mixed with normal serum, incu- 
bated for 22 hr at 4°C, and aliquoted for C4d/C4, 
CI~CI~-(CI INH)2, and hemolytic C4 assays. As 
shown in Table V, results from all three tests 
showed substantial complement activation at 4°C 
after mixing the redissolved PEG precipitate from 
patient 1 with normal serum, whereas the PEG 
precipitate from normal serum (B.Z.) did not have 
this effect. This indicates that the CDAC factor(s) is 
included among the substances precipitated by 
2.5% PEG. 
Table V. Activation of Complement in Normal Serum by 2.5% Polyethylene Glycol (PEG) Precipitate of Patient 1 Serum 
Pt. 1 Pt. 1 ppt. + KMs e + KMs + KMs + Nls  ppt f  + 
ppt. ~ VB ++d Pt. 1 ppt a VB ++ Nls  ppt f  VB ++ KMs b'c 
C4d/C4 ratio ND g ND 2.12 1.0 1.0 1.0 
C 1 ~-Clf'--(CI INH)2 
(ELISA units) 0 0 428 33 38 0 31 
Hemolytic C4 (% normal) 0 < 1 49 46 0 86 
~Redissolved patient 1 PEG precipitate. 
bNot incubated at 4°C. All others incubated for 24 hr at 4°C. 
~Undiluted. 
aEqual volume of Veronal buffer with Ca 2+ and Mg 2+. 
eNormal serum. 
~Redissolved PEG precipitate from another normal serum (BZ). 
gNot detectable; rockets too small to quantitate. 
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Table VI. Inhibition of CDAC by Heat and Restoration by C1 
Unheated serum Heated 15 min at 56°C 
2 hr at 4°C 
Not 2 hr at Not 2 hr at 2 hr at 4°C + heated 
incubated 4°C incubated 4°C + C1 CI 
C4d/C4 ratio 1.04 1.83 
Clg-C lf'-(Cl INH)2 46" 121 
Hemolytic C4 
(% normal) 66 21 
1.77 1.81 2.67 
- 5  -5  105 





In view of the significantly low levels of hemo- 
lytic C4 in our patients' sera and the variable and 
sometimes almost-normal levels of hemolytic C2 
and C1, consideration was given to the possible 
presence of a cold-reactive autoantibody to C4 
causing secondary activation of the classical path- 
way. This was explored by a series of more than 30 
ELISA tests using wells coated with human C4 or 
with goat anti-human C4, the latter being employed 
to test for possible IgG:C4 complexes. Patient 1 
serum usually gave higher OD readings than control 
sera, but it also gave higher OD measurements in 
wells coated with various heterologous materials: 
specific autoantibodies to C4 could not be demon- 
strated. 
Considering the possibility that CDAC might 
have a direct effect on C4 other than through an 
autoantibody mechanism, the effect of heating pa- 
tient 1 serum at 56°C for 15 min was examined. As 
expected, heating per se caused some C4 cleavage 
and loss of C4 hemolytic activity in addition to loss 
of CDAC (Table VI), but CDAC activity was re- 
stored by the addition of C1 but not by heat 
inactivated C1. This requirement for C1, which was 
reproduced in another experiment, is characteristic 
for classical complement pathway activation and 
opposes a direct effect of CDAC factor(s) on C4 or 
C4 binding protein. 
Effect of  a CDAC Factor(s) on Other Tests 
Since CDAC factor(s) may be a form of aggre- 
gated IgG, patient 1 serum obtained at 37°C was 
incubated for 3 or 5 hr at either 4 or 37°(2, and the 
effect on Raji cell tests was noted. The positive 
results, averaging 197 p.g AHG Eq/ml (normal, <50 
AHG Eq/ml), were essentially the same after incu- 
bation at either temperature. Likewise chilling the 
serum for 3 or 5 hr at 4°C did not change the 
borderline results of patient l 's  CIq binding assay. 
Since FACS analyses involve incubating cells in the 
cold and about 26% of patient l 's  lymphoid cells did 
not demonstrate the usual markers, the effect of 
incubating normal peripheral WBC with her hep- 
arinized plasma for 1.5 hr at 4°C was determined to 
see if her plasma might interfere with this test. 
However, there was no change in the percentage of 
cells expressing CD3, CD4, CD8, or CD19 markers 
as compared with unincubated cells or cells incu- 
bated with normal plasma. 
DISCUSSION 
Since CDAC is an in vitro phenomenon, afflicted 
individuals do not experience difficulty upon expo- 
sure to cold as in some other immune cryopathies 
such as cryoglobulinemia, cryofibrinogenemia, cold 
urticaria, or cold hemolysin syndrome. CDAC also 
clearly differs in mechanism from cases of cold- 
promoted activation (CPA) of blood coagulation 
factor VII (24) mediated through contact system 
activation and from cold-dependent consumption of 
C3 (25) mediated through the alternative comple- 
ment pathway. Hishitani et al. (26) have reported 
that the occurrence of a CDAC-type phenomenon 
in patients with liver disease often is associated 
with precipitable mixed cryoglobulins. However, 
centrifugation of serum from our patients I and 2 
after 7 days at 4°C repeatedly yielded no visible 
precipitate, and others have failed to find cryopre- 
cipitates in cases not associated with liver disease. 
Another difference between CDAC and some cases 
of cryoglobulinemia is a decreased level of Clq and 
C4 antigen in the latter (27), whereas the lack of 
immune complex sequestration in vitro results in 
normal values in CDAC even though split products 
can be detected and hemolytic activity is compro- 
mised. Thus, in accord with most other investiga- 
tors, we have used the term CDAC in a more 
restricted sense which excludes cryoglobulinemia 
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and the cold hemolysin syndrome. Perhaps a better 
term would be "idiopathic cold-dependent activa- 
tion of complement." 
CDAC was initially recognized by discrepant 
CH50 and hemolytic C4 values between serum ob- 
tained at 4°C and those measured in EDTA plasma. 
Here it has been shown that measurements of 
C4d/C4 ratios, C4a, C3a, and CIg--CI~-(CI INH) 2 
complexes also can be used to document CDAC 
and that results obtained by these various methods 
parallel each other. No doubt other tests of classical 
complement pathway activation also could be uti- 
lized. The choice of which procedure to use there- 
fore becomes largely a matter of convenience, 
rocket immunoelectrophoresis for C4d/C4 ratios 
and CHso measurements being relatively simple. 
Hemolytic C4 measurements clearly provide the 
greatest sensitivity, but for some research purposes 
this can be disadvantageous; e.g., some lots of 
serum already had low hemolytic C4 values when 
blood supposedly obtained and processed at 370(2 
was not meticulously handled, and in some in- 
stances there was so much loss of hemolytic C4 
activity at 4°C that it was difficult to appreciate the 
difference from results at 13°C that were more 
easily recognized by other methods (Fig. 2). This 
may be one reason why previous investigators have 
not noted that the optimal temperature for CDAC 
may be between 4°C and room temperature. Possi- 
bly more of the factor(s) responsible for CDAC 
aggregates at the lower temperature (i.e., 4°C), but 
consequent complement activation is enhanced at a 
higher temperature (e.g., 13°C). The data indicating 
complement activation when normal serum is 
mixed with CDAC serum at 4°(2 (Table III) confirm 
similar previous results of Kitamura et al. (8) and 
Atkinson et  al. (10). The opportunity to test serum 
from patient 1 over a period of more than 5 years 
establishes that CDAC may be more than a tran- 
sient phenomenon. 
Our observation that CDAC activity is reduced 
by adsorption with streptococcal protein G-Sepha- 
rose (Table IV) supports the conclusion of Atkinson 
et  al. (10) that it is IgG based on partial purification 
by ammonium sulfate precipitation at 4°C followed 
by DEAE column chromatography at room temper- 
ature. The additional observation that CDAC activ- 
ity is precipitated by 2.5% PEG strongly implies 
that polymeric IgG is involved, since monomeric 
IgG would not be expected to precipitate signifi- 
cantly at this PEG concentration (28). The presence 
of CDAC activity in 2.5% PEG precipitates, as 
shown by mixing with normal serum (Table V), 
augments the finding of Takemura et al. (12) that 
such precipitates are anticomplementary. In inter- 
preting these results it should be noted that, in 
addition to precipitating proteins, PEG has been 
reported to enhance the aggregation of IgG by IgM 
rheumatoid factor (29). Hishitani et al. (26) reported 
that the precipitable cryoglobulin in their (mainly) 
liver disease patients which produced features of 
CDAC was a mixed cryoglobulin consisting of IgM 
and polyclonal IgG. Patient 1 serum, however, had 
only minimal rheumatoid factor activity, and the 
partial purification procedure employed by Atkin- 
son et al. (10) should largely exclude IgM. Many 
monoclonal IgG cryoimmunoglobulins are IgG3, 
but patient 1 did not have an elevated IgG3 serum 
level. Accordingly, one may speculate that the 
factor(s) responsible for CDAC in our patients, and 
in others without cryoprecipitates, contains poly- 
meric IgG in a form too small or otherwise incapa- 
ble of precipitating spontaneously in the cold. An 
alternative would be antigen-containing immune 
complexes of similar size and physical properties. 
In patient 1, however, the extensive testing noted 
above for antibodies to many exogenous and autol- 
ogous antigens has yielded negative results. Re- 
gardless of the exact nature of the CDAC factor(s) 
in these patients, they appear to act through activa- 
tion of the classical complement pathway. Unex- 
pectedly high hemolytic C2 levels in relation to 
hemolytic C4 have also been noted in patients with 
hereditary angioedema (30) and might be due to 
reduced cleavage of C2 in the absence of C4. The 
cascade principle of complement activation of 
course would predict less evidence for C1 than C4 
activation. Autoantibodies to C4 with secondary 
activation of the classical pathway could not be 
demonstrated. 
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